Aller au contenu principal
Profil bibliographique

Soon-Hin How

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

6Publications signalées
724Citations signalées
1Affiliations récentes

Les institutions déclarées

Les domaines associés

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchAsthma and respiratory diseasesBone health and osteoporosis researchLung Cancer Diagnosis and Treatment

Les publications récentes

Accès ouvert 2026 article OpenAlex

Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis

Hidetoshi Hayashi, Byoung Chul Cho, Yu Jung Kim, Se-Hoon Lee et autres

BACKGROUND: Approximately 60 % of lung cancer cases occur in Asia, indicating an epidemiological disparity and need for effective therapies. Amivantamab-lazertinib is approved for first-line EGFR-mutated advanced non-small cell lung cancer (NSCLC) in many countries. In the protocol-specified final overall survival (OS) …

jp, kr, th, my, cn, tw, tr, in, us (code pays fourni par la source)

3 citations Lung Cancer
2025 article OpenAlex

Overall Survival with Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC

James Chih‐Hsin Yang, Shun Lu, Hidetoshi Hayashi, Enriqueta Felip et autres

BACKGROUND: (epidermal growth factor receptor)-mutated advanced non-small-cell lung cancer (NSCLC) was significantly improved with amivantamab-lazertinib as compared with osimertinib. Results of the protocol-specified final overall survival analysis in this trial have not been reported. METHODS: -mutated (exon 19 deletion or L858R substitution), …

tw, cn, jp, es, us, fr, kr, ua, th, my, ar, br, it, de, au, in, mx, pt, ru, tr, gb, ca (code pays fourni par la source)

136 citations New England Journal of Medicine
Accès ouvert 2024 article OpenAlex

Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC

Byoung Chul Cho, Shun Lu, Enriqueta Felip, Alexander I. Spira et autres

Background Amivantamab plus lazertinib (amivantamab–lazertinib) has shown clinically meaningful and durable antitumor activity in patients with previously untreated or osimertinib-pretreated EGFR (epidermal growth factor receptor)–mutated advanced non–small-cell lung cancer (NSCLC). Methods In a phase 3, international, randomized trial, we assigned, in a …

cn, us, kr (code pays fourni par la source)

453 citations New England Journal of Medicine
Accès ouvert 2019 article OpenAlex

Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study

Gwo Fuang Ho, Chee-Shee Chai, Adlinda Alip, Mohd Ibrahim A. Wahid et autres

BACKGROUND: This study aimed to evaluate the efficacy, side-effects and resistance mechanisms of first-line afatinib in a real-world setting. METHODS: This is a multicenter observational study of first-line afatinib in Malaysian patients with epidermal growth factor receptor (EGFR)-mutant advanced non-small cell lung …

my (code pays fourni par la source)

44 citations BMC Cancer
Accès ouvert 2018 article OpenAlex

Melioidosis in Malaysia: Incidence, Clinical Challenges, and Advances in Understanding Pathogenesis

Sheila Nathan, Sylvia Chieng, Paul Vijay Kingsley, Anand Mohan et autres

Malaysia is an endemic hot spot for melioidosis; however, a comprehensive picture of the burden of disease, clinical presentations, and challenges faced in diagnosis and treatment of melioidosis is not available. This review provides a nonexhaustive overview of epidemiological data, clinical studies, …

my (code pays fourni par la source)

77 citations Tropical Medicine and Infectious Disease
Accès ouvert 2012 article OpenAlex

Bone mineral density in asthmatic patients on inhaled corticosteroids in a developing country

Yeh Chunn Kuan, Soon-Hin How, AbdulAziz Azian, Chong Kin Liam et autres

INTRODUCTION: Prolonged use of oral corticosteroids is a risk factor for osteoporosis. However, the effect of inhaled corticosteroids (ICS) on bone mineral density (BMD) of asthmatic patients remains controversial. OBJECTIVES: We aimed to determine the prevalence of osteopenia and osteoporosis in our …

my (code pays fourni par la source)

11 citations Annals of Thoracic Medicine

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.